Anti-beta2- glycoprotein I autoantibodies more correlates with strokes in antiphospholipid syndrome

ABSTRACT

To determine the significance of testing for anti-beta-2 glycoprotein I dependent [abeta2-GPI] among stroke patients of antiphospholipid syndrome [APS]. Fifty selected patients with strokes and 30 healthy individuals were tested for lgG isotype of anticardiolipin [aCL], abeta2-GPI, and antiphosphatidyl serine [aPS] autoantibodies. The study was conducted in the Postgraduate Laboratory Center, College of Medicine, and University of Dohuk, Iraq during April 2005. The indirect solid phase enzyme-linked immuno-sorbent assay [ELISA] technique was used for the detection of lgG aCL, abeta2-GPI, and aPS. The studied cases and controls were under 50 years of age and had no recognizable risk factors. One or more of the tested APLAs were detected in 14/50 [28%] of cases with stroke. The lgG aCL was detected in 11/50 [22%], IgG abeta2-GPI in 14/50 [28%], and IgG aPS in 9/50 [18%] of the studied patients. However, IgG aCL was detected in 2/30 [6.7%] of controls with absence of other antiphospholipids antibodies [APLAs]. All IgG aPS positive cases [9/14, 18%] were found to be positive for IgG abeta2-GPI and IgG aCL markers. Moreover, all IgG aCL positive cases [11/50, 22%] were positive for IgG abeta2-GPI marker. On the other hand, IgG abeta2-GPI as a sole marker was detected in another 3 positive APLAs cases with [3/14, 21.4%]. In this study, IgG abeta2-GPI autoantibodies were found to correlate more with stroke cases of APS than other APLAs. These findings necessitate testing for this marker and ascertain the evidence accumulating which would assign a central role played by abeta2-GPI in strokes of APS